In recent years, sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a promising pharmacological innovation initially targeted at glycemic control in type 2 diabetes mellitus (T2DM) (Aguilar-Gallardo et al., 2022). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.